Another PD-1 inhibitor, camrelizumab, plus a tyrosine kinase inhibitor (TKI), apatinib, was reported to effectively prolong the survival of patients with mid- and advanced-stage HCC with good tolerance (143). Here, PDCD1 is linked to hepatocellular carcinoma.